This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsagarakis, S. Articles by Thalassinos, N. Search for Related Content PubMed PubMed Citation Articles by Tsagarakis, S. Articles by Thalassinos, N.

A Reappraisal of the Utility of Somatostatin Receptor Scintigraphy in Patients with Ectopic Adrenocorticotropin Cushing’s Syndrome

Departments of Endocrinology, Diabetes, and Metabolism (S.T., M.C., N.T.), Nuclear Medicine (H.G., F.R., I.H.), Radiology (C.M.), Pathology (D.R.), and Thoracic and Vascular Surgery (I.B.), Evangelismos Hospital, 10676 Athens, Greece

Address all correspondence and requests for reprints to: Dr. S. Tsagarakis, Department of Endocrinology, Diabetes, and Metabolism, Evangelismos Hospital, 10676 Athens, Greece. E-mail: stsagara{at}otenet.gr.

Ectopic ACTH hypersecretion is a rare cause of Cushing’s syndrome. Bronchial carcinoids are the most common neoplasms causing the occult ectopic ACTH syndrome (EAS). Localization of these tumors is often difficult. The diagnostic utility of somatostatin receptor scintigraphy (SRS) in EAS has been studied in a limited number of patients with conflicting results. Herein we report our experience with 12 consecutive cases. Histological confirmation was obtained in nine patients, the majority being bronchial carcinoids. Among the seven patients with histologically confirmed bronchial carcinoids, SRS was performed in six patients. In three patients SRS correctly localized a bronchial carcinoid tumor at presentation. In the remaining three it became positive after 8, 22, and 27 months during follow-up. In two patients SRS was positive without any finding in the corresponding conventional imaging study. In two patients positive computed tomography/magnetic resonance imaging preceded SRS localization. There was no false positive SRS. Among three patients with highly suspected EAS, SRS was positive in one. Both patients with EAS due to medullary thyroid carcinoma had focal positive uptake. In summary, in this study a substantial number of patients had positive tumor localization by SRS. Therefore, SRS is a useful tool in the evaluation of patients with EAS.

Current address for C.M.: Second Department of Radiology, University of Athens, 10676 Athens, Greece.

Abbreviations: CT, Computed tomography; EAS, ectopic ACTH syndrome; MRI, magnetic resonance imaging; MTC, medullary thyroid carcinoma; SRS, somatostatin receptor scintigraphy.

This article has been cited by other articles:

				M. Boscaro and G. Arnaldi Approach to the Patient with Possible Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3121 - 3131. [Abstract] [Full Text] [PDF]

				C de Bruin, R A Feelders, A M Waaijers, P M van Koetsveld, D M Sprij-Mooij, S W J Lamberts, and L J Hofland Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro J. Mol. Endocrinol., January 1, 2009; 42(1): 47 - 56. [Abstract] [Full Text] [PDF]

				C. Waintrop, F. Tenenbaum, J. Coulot, O. Vignaux, C. Blanchet, P. Legmann, B. Richard, and X. Bertagna IMAGE IN ENDOCRINOLOGY: Localization of an Occult Adrenocorticotropin-Secreting Carcinoid Tumor with Somatostatin Receptor Scintigraphy Using Single-Photon Emission Computed Tomography/Computed Tomographic Image Scanning J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3271 - 3272. [Full Text] [PDF]

				M. B. C C. Neto, M. C. Machado, F. Mesquita, N. R. de Castro Musolino, A. C. Toscanini, G. Ochman, V. A. S Cescato, R. Marino Jr, and M. J. Teixeira Thymus hyperplasia after resolution of hypercortisolism in ACTH-dependent Cushing's syndrome: the importance of thymic vein catheterization. Eur. J. Endocrinol., June 1, 2006; 154(6): 807 - 811. [Abstract] [Full Text] [PDF]

				H. Orlefors, A. Sundin, U. Garske, C. Juhlin, K. Oberg, B. Skogseid, B. Langstrom, M. Bergstrom, and B. Eriksson Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3392 - 3400. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				K. Pacak, I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, and L. K. Nieman The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-D-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing's Syndrome J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2214 - 2221. [Abstract] [Full Text] [PDF]